Southborough, Massachusetts-based Corrona LLC, independent specialists in the compilation of real-world evidence and consulting on auto-immune disorders, is represented at EULAR 2016 — the Annual European Congress of Rheumatology June 8-11 in London — by 13 clinical researchers showcasing their research. EULAR 2016 is expected to be this year’s biggest rheumatology event in Europe with an estimated 14,000 delegates in attendance from more than 120 countries.
More than 4,300 abstracts were submitted to the London congress, and more than 190 sessions and poster tours are on offer. The Corrona EULAR presentations represent the cumulative effort of 654 practicing rheumatologists in the U.S. who, over the last 15 years, have collected longitudinal, randomized, controlled-trial quality clinical data on their treatment of rheumatic disease patients.
Two of these abstracts were accepted for podium presentation, and an additional 13 as poster displays, three of which are being highlighted on poster tours.
Since its launch in 2000, the Annual European Congress of Rheumatology has become the primary platform for the exchange of scientific and clinical information on rheumotology in Europe. The Congress is a forum facilitating interaction among medical doctors, scientists, people with arthritis or rheumatism, other health professionals, and representatives of the pharmaceutical industry.
The EULAR Congress’ scientific program covers a wide array of topics including clinical innovations and translational and basic science.
“The Corrona team appreciates that the continued data collection efforts of our rheumatology investigators have provided the foundation for our research programs in areas such as comparative effectiveness and safety of novel therapies,” said Corrona Chief Scientific Officer Jeff Greenberg, MD, MPH, in a release.
Work presented at the EULAR 2016 meeting is derived from Corrona’s rheumatoid arthritis and psoriatic arthritis/spondyloarthritis registries, with the podium presentations focused on the impact and influence rheumatoid arthritis disease activity has on infection risk, and explores the ability of biomarkers to predict response to biologic medications.
Other issues affecting the rheumatoid arthritis patient population include disease activity and treatment pattern trends; treatment acceleration delays; treat to target strategy-related outcomes; comorbidity influences; and an evaluation of disease-modifying anti-rheumatic drugs’ comparative effectiveness.
The Corrona team’s psoriatic arthritis/spondyloarthritis, EULAR 2016 presentations are focused on unique patient subgroup characterizations, various treatment patterns, an evaluation of biologic medication persistency, and evidence of symptom rebound after low disease activity has been achieved and biologic treatment discontinued.
Corrona is an independent provider of registries without ownership links to the pharmaceutical industry, so its registries function without direct influence from pharmaceutical companies on research outcomes.
The company notes that pharmaceutical companies may request data analysis on any agent in the marketplace, but if the analysis results are released into the public domain as a scientific abstract or manuscript, Corrona mandates that an independent academic lead have absolute and final responsibility for results generated — a process that ensures data derived from Corrona on comparative effectiveness or safety outcomes retains the objective sanctity and independence expected of a national database.
Corrona’s flagship registry since 2001 is the US Rheumatoid Arthritis (RA) Registry — the largest real-world observational database in rheumatoid arthritis, offering deep clinical insights, and which which contains data from more than 40,000 patients and 130,000-plus patient-years of detailed clinical observational data from physicians and patients at 80 rheumatology sites, 12 university sites, and 68 private practice and affiliated sites.
Other Corrona registries in the autoimmune space include:
- U.S. Certain RA Registry, which contains biosamples on 2,800 biologic or small molecule DMARD drug initiations;
- Japan RA Registry, launched in 2016 with a study of 2,000 patients;
- U.S. Psoriatic Arthritis and Spondyloarthritis (PsA/SpA) Registry, launched in 2013, containing data on over 2,500 patients;
- U.S. Psoriasis Registry, launched in April 2015 in conjunction with the National Psoriasis Foundation, which expects to collect data on over 10,000 patients being treated with biologics;
- U.S. Inflammatory Bowel Disease (IBD) – Crohn’s Disease and Ulcerative Colitis Pilot Registry, which is expecting full launch this year or in 2017.
Corrona says its subscription model assures independent and credible data and analysis for subscribers, with economies of scale and efficiencies of process built into the registries’ design and implementation — advantages the company maintains cannot be achieved by any pharmaceutical company-sponsored registry. Corrona’s dataset contains randomized controlled trial quality standardized outcome measures that can be used to quantify safety events, assess treatment effectiveness, address pharmaco-vigilance reporting requirements, and provide insight into treatment decisions.
Along with annual subscriptions to the Corrona database, plus consulting through their biostatistics team, the company will work with clients to develop research plans to explore key questions of interest on their products or comparators. Corrona’s validated clinical outcomes help clients understand different physician/patient segments and opportunities for growth, with a major focus of their work linking deep clinical data with claims and other data sources.
For more information, visit:
http://www.corrona.org
A EULAR 2016 Congress app and itinerary planner is available for iOS, Android, and Windows Mobile, containing all the information attendees need to navigate through the four-day event, including session details, satellite symposiums, exhibitions, and useful service information around the Congress. The information from the planner can be imported into the app. For more information and download links, visit this link.
